Get started
Author

Elizabeth L. Kyran

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
2024 · Ksenija Nesic, John J. Krais, et al. · Molecular Cancer · 36
PDF
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2022 · Gwo Yaw Ho, Elizabeth L. Kyran, et al. · Cancer Research · 26
PDF
Targeting homologous recombination deficiency in uterine leiomyosarcoma
2023 · Genevieve Dall, Cassandra J. Vandenberg, et al. · Journal of Experimental & Clinical Cancer Research · 22
PDF
Multiple pathological mechanisms contribute to hippocampal damage in the experimental autoimmune encephalomyelitis model of multiple sclerosis
2017 · Elizabeth L. Kyran, Christine Robinson, et al. · Neuroreport · 14
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
2023 · Gwo Yaw Ho, Cassandra J. Vandenberg, et al. · Therapeutic Advances in Medical Oncology · 6
Global analysis of cancer cell responses to USP9X inhibition
2026 · Philipp Schenk, Shane M Devine, et al. · The EMBO Journal · 4
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
2026 · Andrew Farrell, Genevieve Dall, et al. · Journal of Experimental & Clinical Cancer Research · 2
Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencing
2025 · Ksenija Nesic, Franziska Geissler, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy
2020 · Gwo Yaw Ho, Elizabeth L. Kyran, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.
2017 · Gwo Yaw Ho, Elizabeth Lieschke, et al. · Journal of Clinical Oncology · 1
Additional file 2 of High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
2026 · Farrell, Andrew, Dall, Genevieve, et al. · Figshare
Additional file 1 of High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
2026 · Farrell, Andrew, Dall, Genevieve, et al. · Figshare
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
2026 · Farrell, Andrew, Dall, Genevieve, et al. · Figshare
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2025 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2025 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2023 · Gwo Yaw Ho, Elizabeth L. Kyran, et al.
Works count: 31
Citation count: 114
H-index: 5
I10-index: 4
Year
Topic
Type